- 英文名称
- Mafodotin
- 分子式
- C49H76N6O11
- 分子量
- 925.16
- 中文别名
- N-[6-(2,5-二氢-2,5-二氧代-1H-吡咯-1-基)-1-氧代己基]-N-甲基-L-缬氨酰-L-缬氨酰基-(3R,4S,5S)-3-甲氧基-5-甲基-4-(甲氨基)庚酰基-(ΑR,ΒR,2S)-Β-甲氧基-Α-甲基-2-吡咯烷丙酰基-L-苯丙氨酸; MC-MMAF; 化合物MCMMAF; MC-MMAF游离态; 偶联抗体Maleimidocaproyl monomethylauristatin F; (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-methylhexanamido)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoic acid; N-[6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S)-1-carboxy-2-phenylethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl}-3-methoxy-5-methyl-1-oxo-4-heptanyl]-N-methyl-L-valinamide; N-[6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-L-phenylalanine; (2S)-2-[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropan; MaleiMidocaproyl MonoMethylauristatin F; Mc-MMAF; SGD 1269
- 用途
- 作为抗体药物偶联物(ADC)的药物-连接子复合物;由高效微管抑制剂Monomethyl auristatin F(MMAF)与保护基团maleimidocaproyl偶联而成,通过阻断微管聚合抑制细胞分裂,较MMAE毒性低,用于ADC;靶点为Auristatin;体外研究显示其需通过蛋白酶可裂解连接子与靶向肿瘤特异性细胞表面抗原的单克隆抗体偶联后发挥抗肿瘤作用
